Sorption, Degradation, and Transport of Sulfamethazine in Soils and Manure-Amended Soils Warisara Lertpaitoonpan Iowa State University

Total Page:16

File Type:pdf, Size:1020Kb

Sorption, Degradation, and Transport of Sulfamethazine in Soils and Manure-Amended Soils Warisara Lertpaitoonpan Iowa State University CORE Metadata, citation and similar papers at core.ac.uk Provided by Digital Repository @ Iowa State University Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2008 Sorption, degradation, and transport of sulfamethazine in soils and manure-amended soils Warisara Lertpaitoonpan Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Civil and Environmental Engineering Commons Recommended Citation Lertpaitoonpan, Warisara, "Sorption, degradation, and transport of sulfamethazine in soils and manure-amended soils" (2008). Graduate Theses and Dissertations. 11180. https://lib.dr.iastate.edu/etd/11180 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Sorption, degradation, and transport of sulfamethazine in soils and manure- amended soils by Warisara Lertpaitoonpan A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Civil Engineering (Environmental Engineering) Program of Study Committee: Say Kee Ong, Co-major Professor Thomas B. Moorman, Co-major Professor Thomas E. Loynachan Timothy G. Ellis Roy Gu Iowa State University Ames, Iowa 2008 Copyright © Warisara Lertpaitoonpan, 2008. All rights reserved. ii TABLE OF CONTENTS LIST OF TABLES iv LIST OF FIGURES v ACKNOWLEDGEMENTS viii ABSTRACT x CHAPTER 1. INTRODUCTION ………………………………………………… 1 1.1 General introduction…………………………………………………… 1 1.2 Dissertation organization………………………………………………. 3 1.3 References……………………………………………………………... 4 CHAPTER 2. LITERATURE REVIEW ……………………………………......... 7 2.1 Antibiotics usage………………………………………………………. 7 2.2 Environmental and human risks……………………………………….. 8 2.3 Characteristics of sulfamethazine……………………………………… 9 2.4 Environmental concentrations…………………………………………. 14 2.5 Fate of sulfonamides in the environment……………………………… 18 2.5.1 Sorption……………………………………………………….. 18 2.5.2 Impact of soil pH on sorption of sulfonamides……………….. 22 2.5.3 Degradation…………………………………………………… 22 2.6 Transport of sulfonamides……………………………………………... 25 2.7 Summary……………………………………………………………….. 26 2.8 References……………………………………………………………... 27 CHAPTER 3. EFFECT OF ORGANIC CARBON AND PH ON SOIL SORPTION OF SULFAMETHAZINE………………............................................ 39 3.1 Abstract……………………………………………………………….... 39 3.2 Introduction……………………………………………………………. 40 3.3 Materials and methods…………………………………………………. 41 3.3.1 Soil sampling and analysis……………………………………. 41 3.3.2 Chemicals……………………………………………………... 42 3.3.3 HPLC analysis………………………………………………… 43 3.3.4 Batch sorption experiments…………………………………… 43 3.4 Results and discussion…………………………………………………. 45 3.4.1 Sorption isotherms…………………………………………….. 45 3.4.2 Effect of pH…………………………………………………… 46 3.4.3 Model development…………………………………………… 48 3.5 Conclusion…………………………………………………………….. 51 3.6 References…………………………………………………………….. 52 iii CHAPTER 4. DEGRADATION OF SULFAMETHAZINE IN SOIL AND MANURE-AMENDED SOIL ……………………………………………... 67 4.1 Abstract……………………………………………………………….... 67 4.2 Introduction……………………………………………………………. 68 4.3 Materials and methods…………………………………………………. 70 4.3.1 Soil sampling and swine manure…………………………….... 70 4.3.2 Chemicals……………………………………………………... 71 4.3.4 Sulfamethazine effects on microbial respiration……………… 71 4.3.5 Aerobic degradation of SMZ………………………………….. 73 4.3.6 Anaerobic degradation of SMZ……………………………….. 74 4.3.7 Extraction of SMZ…………………………………………….. 75 4.3.8 HPLC analysis………………………………………………… 75 4.3.9 Fate of 14 C-SMZ………………………………………………. 76 4.4 Degradation kinetics…………………………………………………… 77 4.5 Results and discussion…………………………………………………. 78 4.5.1 SMZ effects on microbial respiration…………………………. 78 4.5.2 Aerobic and anaerobic degradation of SMZ…………………... 81 4.5.3 Fate of 14 C-SMZ………………………………………………. 84 4.6 Conclusion……………………………………………………………... 86 4.7 References……………………………………………………………... 87 CHAPTER 5. LEACHING OF SULFAMETHAZINE IN SOIL WITH AND WITHOUT MANURE: EFFECT OF DURATION BETWEEN APPLICATION AND RAIN ……………………………………………………………………….. 104 5.1 Abstract………………………………………………………………… 104 5.2 Introduction……………………………………………………………. 105 5.3 Materials and methods…………………………………………………. 107 5.3.1 Soil and swine manure sampling and analysis………………... 107 5.3.2 Chemicals……………………………………………………... 108 5.3.3 Soil column preparation………………………………………. 108 5.3.4 Leaching study………………………………………………… 109 5.3.5 Samples clean up using SPE…………………………………... 111 5.3.6 Soil extraction…………………………………………………. 111 5.3.7 HPLC analysis………………………………………………… 112 5.4 Results and discussion…………………………………………………. 113 5.5.1 Effect of time duration and manure on SMZ leaching………... 113 5.5.2 Depth distribution of SMZ……………………………………. 115 5.5 Conclusion……………………………………………………………... 117 5.6 References……………………………………………………………... 118 CHAPTER 6. CONCLUSION …………………………………………………... 129 iv LIST OF TABLES CHAPTER 2 Table 1 List of sulfonamides (Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 2001)……………………….. 11 Table 2 Concentrations of sulfonamides in manure, soils, and water ……. 16 Table 3 Sorption coefficients of sulfonamides at various conditions ….… 20 CHAPTER 3 Table 1 Physical-chemical properties of soils…………………………….. 56 Table 2 Estimated sorption coefficients, K d and K oc , with 95 % confidence interval, and Freundlich sorption coefficients (K f), nonlinearity constant (n) for five soils for pH from 5.5 to 9……... 57 + 0 - Table 3 Kd , K d , and Kd for five soils…………………………………… 58 Table 4 Comparison of mean estimated K oc for four soils (excluding Clarion-1) at each pH and the K oc predicted by Eq. 7 using one- sample t test………………………………………………………. 59 Table 5 Comparison of K d reported by other researchers and predicted K d using Eqs. 2 – 5 and Eq. 6………………………………………... 60 CHAPTER 4 Table 1 Degradation rate constants and half-lives of aerobic degradation, and anaerobic degradation of SMZ in soils alone and manure- amended soils (with 95 % confidence interval)………………….. 92 Table 2 Fraction of total 14 C, and 14 C-SMZ in extracts after 28 and 77 days incubation under aerobic and anaerobic conditions, respectively (average with 95 % confidence interval)…………… 93 CHAPTER 5 Table 5.1 Physical-chemical characteristics of soil for each depth increment 124 v LIST OF FIGURES CHAPTER 2 Figure 1 Chemical structures of PABA and sulfonamide group…………... 9 Figure 2 Chemical structure of sulfamethazine and its protonated and deprotonated form………………………………………………... 13 CHAPTER 3 Figure 1 Chemical structure of sulfamethazine and its anionic and cationic forms……………………………………………………………... 61 Figure 2 Sorption isotherms of sulfamethazine for five soils at pH 5.5, 6, 7, 8, and 9. Solid lines show the linear isotherms obtained by least squares regression…………………………………………... 62 Figure 3 Sorption (K d) of sulfamethazine to five soils (Clarion-1, Clarion- 2, Clarion-3, Nicollet, and Harps) as a function of (a) pH, and (b) percent of anionic sulfamethazine in solution……………………. 63 Figure 4 Relationship of sulfamethazine sorption and soil organic carbon.. 64 Figure 5 Relationship of K oc (except for Clarion-1) and soil pH………….. 65 Figure 6 Plot of experimental K d and predicted K d predicted using Eqs. 2 – 5 and Eq. 6……………………………………………………... 66 CHAPTER 4 Figure 1 Structure of sulfamethazine……………………………………… 94 Figure 2 Net cumulative amounts of CO 2 evolved at initial SMZ concentrations of 0.5, 5, 10, 50, 100, and 150 mg kg-1 soil in soils alone and manure-amended soils under aerobic conditions over a 40-day incubation……………………………………………...….. 95 Figure 3 Net cumulative amounts of CO 2 evolved at initial SMZ concentrations of 0.5, 5, 10, 50, 100, and 150 mg kg-1 soil, in soils alone and manure-amended soil under anaerobic conditions over a 80-day incubation…………………………………………………. 96 vi Figure 4 Maximum net cumulative CO 2 evolved from soils alone and manure-amended soils under aerobic (40-day incubation) and anaerobic (80-day incubation) for various SMZ initial concentrations…………………………………………………… 97 Figure 5 Percent of extractable sulfamethazine (SMZ) remaining in (a) soils alone and (b) manure-amended soils, under aerobic conditions, for various initial SMZ concentrations (points are experimental, and solid lines are fitted results of availability adjusted first-order kinetic model)……………………………….. 98 Figure 6 Percent of extractable sulfamethazine (SMZ) remaining in (a) soils alone (b) manure-amended soils, under anaerobic conditions for various initial concentrations (points are experimental, and solid lines are fitting results of availability adjusted first-order kinetic model)……………………………….. 99 Figure 7 Adjusted rate constant (k´´) and initial SMZ concentration in aerobic (28-day incubation) and anaerobic degradation (63-day incubation) experiments for various initial SMZ concentrations…………………. 100 Figure 8 Half-lives (t 1/2 ) and initial SMZ concentration in aerobic (28-day incubation) and anaerobic degradation (63-day incubation) experiments for various initial SMZ concentrations………………….. 101 14 14 14 14 Figure 9 C mass balances for CO 2 evolved, Cextracted, and C bound residues in (a) soils alone and (b) manure-amended soils over 28-day period of aerobic degradation………………………………………. 102 14 14 14 14 Figure 10 C Mass balances for CO 2 evolved, C extracted, and C bound residues in (a)
Recommended publications
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Farrukh Javaid Malik
    I Farrukh Javaid Malik THESIS PRESENTED TO OBTAIN THE GRADE OF DOCTOR OF THE UNIVERSITY OF BORDEAUX Doctoral School, SP2: Society, Politic, Public Health Specialization Pharmacoepidemiology and Pharmacovigilance By Farrukh Javaid Malik “Analysis of the medicines panorama in Pakistan – The case of antimicrobials: market offer width and consumption.” Under the direction of Prof. Dr. Albert FIGUERAS Defense Date: 28th November 2019 Members of Jury M. Francesco SALVO, Maître de conférences des universités – praticien hospitalier, President Université de Bordeaux M. Albert FIGUERAS, Professeur des universités – praticien hospitalier, Director Université Autonome de Barcelone Mme Antonia AGUSTI, Professeure, Vall dʹHebron University Hospital Referee Mme Montserrat BOSCH, Praticienne hospitalière, Vall dʹHebron University Hospital Referee II Abstract A country’s medicines market is an indicator of its healthcare system, the epidemiological profile, and the prevalent practices therein. It is not only the first logical step to study the characteristics of medicines authorized for marketing, but also a requisite to set up a pharmacovigilance system, thus promoting rational drug utilization. The three medicines market studies presented in the present document were conducted in Pakistan with the aim of describing the characteristics of the pharmaceutical products available in the country as well as their consumption at a national level, with a special focus on antimicrobials. The most important cause of antimicrobial resistance is the inappropriate consumption of antimicrobials. The results of the researches conducted in Pakistan showed some market deficiencies which could be addressed as part of the national antimicrobial stewardship programmes. III Résumé Le marché du médicament d’un pays est un indicateur de son système de santé, de son profil épidémiologique et des pratiques [de prescription] qui y règnent.
    [Show full text]
  • Approach to Managing Patients with Sulfa Allergy Use of Antibiotic and Nonantibiotic Sulfonamides
    CME Approach to managing patients with sulfa allergy Use of antibiotic and nonantibiotic sulfonamides David Ponka, MD, CCFP(EM) ABSTRACT OBJECTIVE To present an approach to use of sulfonamide-based (sulfa) medications for patients with sulfa allergy and to explore whether sulfa medications are contraindicated for patients who require them but are allergic to them. SOURCES OF INFORMATION A search of current pharmacology textbooks and of MEDLINE from 1966 to the present using the MeSH key words “sulfonamide” and “drug sensitivity” revealed review articles, case reports, one observational study (level II evidence), and reports of consensus opinion (level III evidence). MAIN MESSAGE Cross-reactivity between sulfa antibiotics and nonantibiotics is rare, but on occasion it can affect the pharmacologic and clinical management of patients with sulfa allergy. CONCLUSION How a physician approaches using sulfa medications for patients with sulfa allergy depends on the certainty and severity of the initial allergy, on whether alternatives are available, and on whether the contemplated agent belongs to the same category of sulfa medications (ie, antibiotic or nonantibiotic) as the initial offending agent. RÉSUMÉ OBJECTIF Proposer une façon d’utiliser les médicaments à base de sulfamides (sulfas) chez les patients allergiques aux sulfas et vérifier si ces médicaments sont contre-indiqués pour ces patients. SOURCES DE L’INFORMATION Une consultation des récents ouvrages de pharmacologie et de MEDLINE entre 1966 et aujourd’hui à l’aide des mots clés MeSH «sulfonamide» et «drug sensitivity» a permis de repérer plusieurs articles de revue et études de cas, une étude d’observation et des rapports d’opinion consensuelles (preuves de niveau III).
    [Show full text]
  • Sulfonamides and Sulfonamide Combinations*
    Sulfonamides and Sulfonamide Combinations* Overview Due to low cost and relative efficacy against many common bacterial infections, sulfonamides and sulfonamide combinations with diaminopyrimidines are some of the most common antibacterial agents utilized in veterinary medicine. The sulfonamides are derived from sulfanilamide. These chemicals are structural analogues of ρ-aminobenzoic acid (PABA). All sulfonamides are characterized by the same chemical nucleus. Functional groups are added to the amino group or substitutions made on the amino group to facilitate varying chemical, physical and pharmacologic properties and antibacterial spectra. Most sulfonamides are too alkaline for routine parenteral use. Therefore the drug is most commonly administered orally except in life threatening systemic infections. However, sulfonamide preparations can be administered orally, intramuscularly, intravenously, intraperitoneally, intrauterally and topically. Sulfonamides are effective against Gram-positive and Gram-negative bacteria. Some protozoa, such as coccidians, Toxoplasma species and plasmodia, are generally sensitive. Chlamydia, Nocardia and Actinomyces species are also sensitive. Veterinary diseases commonly treated by sulfonamides are actinobacillosis, coccidioidosis, mastitis, metritis, colibacillosis, pododermatitis, polyarthritis, respiratory infections and toxo- plasmosis. Strains of rickettsiae, Pseudomonas, Klebsiella, Proteus, Clostridium and Leptospira species are often highly resistant. Sulfonamides are bacteriostatic antimicrobials
    [Show full text]
  • Common Oral Antibiotics for Horses Antibiotics Are Commonly Used In
    Common Oral Antibiotics for Horses Antibiotics are commonly used in horses for a variety of conditions. In order to determine which antibiotic is appropriate for a specific condition, a culture of the affected area needs to be performed. The culture is sent to a lab where the bacteria are grown and identified. A sensitivity test is then performed to find out which antibiotics will be effective. Some of the more common oral antibiotics in horses include trimethoprim sulfa, metronidazole, enrofloxacin, and chloramphenicol. Trimethoprim sulfa (SMZ, TMS, sulfa tabs) is an antibiotic which has a broad spectrum of activity against a variety of bacteria. It is broken down by the liver and excreted in the urine. Side effects of this drug include diarrhea, allergic reactions, and effects on the blood, including decreased number of red blood cells (anemia), decreased number of platelets (thrombocytopenia), and decreased number of white blood cells (leucopenia). Trimethoprim sulfa commonly comes in 960mg tablets. The dose range for horses is 15-30 mg/kg. Generally, 10 tablets administered orally for a 1000lb horse is effective. This medication is given twice a day (every 12 hours) and is best absorbed if given without food. Trimethoprim sulfa may be prescribed by your veterinarian for simple wounds, such as those on the face or legs. Metronidazole is an antibiotic commonly used for anaerobic (bacteria which can grow in the absence of oxygen) infections. For example, deep puncture wounds, respiratory infections, peritonitis, soft tissue infections, and abscesses are infections that often involve anaerobic bacteria.. It is broken down by the liver and excreted in the urine and in the feces.
    [Show full text]
  • Investigation of Hsp90 Structure-Activity Relationships in Epigallocatechin Gallate
    Montclair State University Montclair State University Digital Commons Theses, Dissertations and Culminating Projects 1-2017 Investigation of Hsp90 Structure-Activity Relationships in Epigallocatechin Gallate Arpita Patel Follow this and additional works at: https://digitalcommons.montclair.edu/etd Part of the Chemistry Commons Montclair State University I Investigation of Hsp90 structure-activity relationships in epigallocatechin gallate/ By Arpita Patel A Master’s Thesis Submitted to the Faculty of The College of Science and Mathematics Montclair State University In Partial Fulfillment of the Requirements For the Degree of Master of Science in Chemistry January 2017 College: College of Science and Mathematics Thesis Committee: Department: Chemistry and Biochemistry Thesis Sponsor: David P. Rotella Committee Member: David W. Konas Committee Member: John Siekierka Abstract: (-)-Epigallocatechin gallate (EGCG) is a polyphenolic natural product that inhibits the key chaperone protein Hsp90 by binding to the carboxy terminal portion of the protein. The natural product has modest activity as an Hsp90 inhibitor and there is little information in the literature on structure activity relationships for EGCG analogs. Previous studies from this laboratory provided initial data on the effect of a limited range of changes associated with functional groups, substituents and stereochemistry. The focus of this research is to explore these initial results in more detail with a focus on the synthesis of EGCG analogs with more drug like features. Investigation of Hsp90 structure-activity relationships in epigallocatechin gallate A Thesis Submitted in partial fulfillment of the requirement For the degree of Master of Science in Chemistry By Arpita Patel Montclair State University Montclair, NJ 2017 Table of Contents Section Page Introduction 3 Chemistry 11 Result and discussion 18 Experimental section 20 References 39 Spectral Analysis 42 Introduction Heat shock proteins (Hsps) are proteins that act as chaperones to help regulate the structure and function of other proteins.
    [Show full text]
  • Which Diuretics Are Safe and Effective for Patients with a Sulfa Allergy?
    From the CLINIcAL InQUiRiES Family Physicians Inquiries Network Ron Healy, MD University of Washington, Which diuretics are safe Seattle; Alaska Family Medicine Residency, Anchorage and effective for patients Terry Ann Jankowski, MLS University of Washington, Seattle with a sulfa allergy? Evidence-based answer Diuretics that do not contain a sulfonamide subsequent allergic reactions to commonly group (eg, amiloride hydrochloride, used sulfonamide-containing diuretics eplerenone, ethacrynic acid, spironolactone, (eg, carbonic anhydrase inhibitors, loop and triamterene) are safe for patients with an diuretics, and thiazides) (strength of allergy to sulfa. The evidence is contradictory recommendation: C, based on case series ® as to whether a history Dowdenof allergy to Healthand poor Media quality case-control and cohort sulfonamide antibiotics increases the risk of studies). Copyright Clinical commentaryFor personal use only Are all sulfa drugs created equal? agents and off-patent, with no company Historical bromides commonly fall by the to take up their cause, no one has been FAST TRACK wayside as better evidence becomes willing to challenge outdated package Reasonable available. Who would have thought 15 insert warnings. years ago that we would be promoting As clinicians who regularly work evidence supports beta-blockers for patients with congestive without a net, we are accustomed to what many of us heart failure? prescribing medications in less than ideal are doing: Using Likewise, with closer inspection, we circumstances. Thankfully, reasonable cheap thiazides have learned that not all sulfa drugs are evidence is available to support what many created equal. The stereospecificity due of us are already doing—using cheap for patients to the absence of aromatic amines in thiazides for patients despite a history of with a history common diuretics means they are safe sulfa allergy.
    [Show full text]
  • BCBSM Clinical Drug List (Formulary)
    Blue Cross Blue Shield of Michigan ® ® Clinical Drug List (Formulary) Please note that this listing of medications contained in this Blue Cross Blue Shield of Michigan Clinical Drug List (Formulary) is current at the time that the list is posted to this website, and is subject to change. INTRODUCTION Blue Cross Blue Shield of Michigan is pleased to provide the Clinical Drug List as a useful reference and educational tool to assist providers in selecting cost-effective therapies. Please familiarize yourself with this information. To provide effective high-quality care, this Clinical Drug List requires the continuing support of physicians and phar - macists. Your questions and suggestions are welcome. PREFACE The Blue Cross Blue Shield of Michigan Clinical Drug List is a list of FDA-approved prescription drug medications reviewed by the BCBSM/BCN Pharmacy and Therapeutics (P&T) Committee. The Clinical Drug List will assist in maintaining the quality of patient care and containing cost for the member’s drug benefit plan. Providers, physicians, and pharmacists are encouraged to refer to the Clinical Drug List when selecting prescription drug therapy for eligible plan members. Physicians are encouraged to prescribe med ications included in the Clinical Drug List whenever possible. If a prescrip tion is written for a nonpreferred drug or for a drug or dose not recommended for use in the elderly or pregnant, phar macists are encouraged to contact the physician. The benefit plan administrator will monitor provider- specific drug list prescribing and communicate with providers to optimize compliance. The Clinical Drug List is divided into major therapeutic categories (chapters) for easy use.
    [Show full text]
  • Resistance to Trimethoprim and Sulfonamides Ola Sköld
    Resistance to trimethoprim and sulfonamides Ola Sköld To cite this version: Ola Sköld. Resistance to trimethoprim and sulfonamides. Veterinary Research, BioMed Central, 2001, 32 (3-4), pp.261-273. 10.1051/vetres:2001123. hal-00902703 HAL Id: hal-00902703 https://hal.archives-ouvertes.fr/hal-00902703 Submitted on 1 Jan 2001 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Vet. Res. 32 (2001) 261–273 261 © INRA, EDP Sciences, 2001 Review article Resistance to trimethoprim and sulfonamides Ola SKÖLD* Division of Microbiology, Department of Pharmaceutical Biosciences, Biomedical Center, Uppsala University, PO Box 581, SE-751 23 Uppsala, Sweden (Received 7 December 2000; accepted 7 February 2001) Summary – Sulfonamides and trimethoprim have been used for many decades as efficient and inex- pensive antibacterial agents for animals and man. Resistance to both has, however, spread exten- sively and rapidly. This is mainly due to the horizontal spread of resistance genes, expressing drug- insensitive variants of the target enzymes dihydropteroate synthase and dihydrofolate reductase, for sulfonamide and trimethoprim, respectively. Two genes, sul1 and sul2, mediated by transposons and plasmids, and expressing dihydropteroate synthases highly resistant to sulfonamide, have been found.
    [Show full text]
  • Abstract Characterization of Potential Anti-Infective
    ABSTRACT CHARACTERIZATION OF POTENTIAL ANTI-INFECTIVE AGENTS OF Burkholderia pseudomallei TARGETING IspF Joy Michelle Blain, Ph.D. Department of Chemistry and Biochemistry Northern Illinois University, 2016 James R. Horn, Co-Director Timothy J. Hagen, Co-Director There is an urgent need for new anti-infective agents. Pathogenic organisms continue to develop resistance to modern-day antibiotics, while there has been a significant decline in the development of antibiotics over the last 30 years. One particular pathway of interest in the development of new antibiotics is the biosynthesis of isoprenoids. These compounds are essential chemical building blocks in pathogenic organisms such as Plasmodium falciparum, Mycobacterium tuberculosis, and Burkholderia pseudomallei. Notably, there are two distinct pathways in the biosynthesis of isoprenoids called the Mevalonate (MVA) pathway and the 2C-methyl-D-erythritol phosphate (MEP) pathway. The MEP pathway enzymes are attractive targets in developing novel anti-infective agents due to the fact that humans only use the MVA pathway to produce isoprenoids. Burkholderia pseudomallei is a Gram-negative bacterium found in untreated water and soil in Southeast Asia and northern Australia. The bacterium has been classified as a category B bioterrorism agent/disease by the category B bioterrorism agent/disease by the Centers for Disease Control and Prevention. Antibiotic resistance to traditional anti-microbial agents in such pathogenic organisms has increased due to the primary mechanisms of resistance, which are enzyme inactivation, drug efflux from the cell, and target deletion. Consequently, new anti- infective agents targeting B. pseudomallei are of great interest. The focus of this research project was to examine the inhibition of the fifth enzyme in the MEP pathway, 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) using small molecules that were developed based on fragment hits and structure activity relationships (SAR).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]